Brief: BrainsWay Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21
13/11/2025 11:47
Nov 13 (Reuters) - Brainsway Ltd BWAY.TA: BRAINSWAY RECEIVES FDA CLEARANCE OF DEEP TMS™ AS ADJUNCT THERAPY FOR MAJOR DEPRESSIVE DISORDER (MDD) IN ADOLESCENTS AGED 15 TO 21 Source text: ID:nGNX2CvSNd Further company coverage: BWAY.TA ((reuters.briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)